公开(公告)号：US10758557B2

公开(公告)日：2020-09-01

申请号：US16440659

申请日：2019-06-13

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/7076 ,  A61K31/708 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/21 ,  G03C1/005

Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US10513534B2

公开(公告)日：2019-12-24

申请号：US14047862

申请日：2013-10-07

Applicant: IDENIX PHARMACEUTICALS LLC ,  Centre National De La Recherche Scientifique ,  UNIVERSITE DE MONTPELLIER

Inventor： Gilles Gosselin ,  Christophe Claude Parsy ,  Francois-Rene Alexandre ,  Houcine Rahali ,  Jean-Francois Griffon ,  Dominique Surleraux ,  Cyril B. Dousson ,  Claire Pierra ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistair James Stewart

IPC: C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H19/11 ,  C07H19/16 ,  C07H19/173 ,  C07H19/20 ,  C07H19/213 ,  A61K31/7072 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7076 ,  C07H19/14 ,  A61K31/7064 ,  C07H19/12 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/403 ,  A61K31/497 ,  A61K31/7105 ,  C07H19/23

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

公开(公告)号：US20190290670A1

公开(公告)日：2019-09-26

申请号：US16440659

申请日：2019-06-13

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/708 ,  A61K38/21 ,  A61K31/7056 ,  C07H19/10 ,  C07H19/20 ,  C07H19/16 ,  A61K31/7068 ,  C07H19/06 ,  C07H19/04 ,  A61K45/06 ,  A61K31/7076 ,  A61K31/7072

Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US20190183912A1

公开(公告)日：2019-06-20

申请号：US16327631

申请日：2017-08-22

Applicant: Merck Sharp & Dohme Corp. ,  IDENIX PHARMACEUTICALS LLC

Inventor： Daniel Da Costa ,  Cyril B. Dousson ,  David Dukhan ,  Jean-Laurent Paparin ,  Houcine Rahali ,  Izzat Raheem

IPC: A61K31/675 ,  A61P31/12

CPC classification number: A61K31/675 ,  A61K45/05 ,  A61K45/06 ,  A61P31/00 ,  A61P31/12 ,  C07F9/65616

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

公开(公告)号：US10251903B2

公开(公告)日：2019-04-09

申请号：US15519846

申请日：2015-10-20

Applicant: MERCK SHARP & DOHME CORP. ,  IDENIX Pharmaceuticals LLC ,  Bryon L. Simmons ,  Kevin R. Campos ,  Artis Klapars ,  Alistair J. Stewart ,  Benjamin A. Mayes ,  Peter E. Maligres ,  Alan Hyde ,  Steven Mark Silverman ,  Yong-Li Zhong ,  Adel M. Moussa ,  Kenneth Baker ,  Kara Van Valkenburg

Inventor： Bryon L. Simmons ,  Kevin R. Campos ,  Artis Klapars ,  Alistair J. Stewart ,  Benjamin A. Mayes ,  Peter E. Maligres ,  Alan Hyde ,  Steven Mark Silverman ,  Yong-Li Zhong ,  Adel M. Moussa ,  Kenneth Baker ,  Kara Van Valkenburg

IPC: C07H19/10 ,  A61K31/7052 ,  C07H1/00 ,  C08K3/08

Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

公开(公告)号：US20180362562A1

公开(公告)日：2018-12-20

申请号：US15781985

申请日：2016-12-05

Applicant: Merck Sharp & Dohme Corp. ,  Idenix Pharmaceuticals LLC

Inventor： Izzat Tiedje Raheem ,  Timothy J. Hartingh ,  John Schreier ,  Jean-Laurent Paparin

IPC: C07F9/6561 ,  A61K45/06 ,  A61P31/18 ,  A61K31/675

Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

公开(公告)号：US20170246198A1

公开(公告)日：2017-08-31

申请号：US15519846

申请日：2015-10-20

Applicant: Bryon L. Simmons ,  Kevin R. Campos ,  Artis Klapars ,  Alistair J. Stewart ,  Benjamin A. Mayes ,  Peter E. Maligres ,  Alan Hyde ,  Steven Mark Silverman ,  Yong-Li Zhong ,  Adei M. Moussa ,  Kenneth Baker ,  Kara van Valkenburg ,  IDENIX PHARMACEUTICALS LLC

Inventor： Bryon L. SIMMONS ,  Kevin R. CAMPOS ,  Artis KLAPARS ,  Alistair J. STEWART ,  Benjamin A. MAYES ,  Peter E. MALIGRES ,  Alan HYDE ,  Steven Mark SILVERMAN ,  Yong-Li ZHONG ,  Adel M. MOUSSA ,  Kenneth BAKER ,  Kara van VALKENBURG

IPC: A61K31/7052 ,  C08K3/08 ,  C07H19/10

CPC classification number: A61K31/7052 ,  C07H1/00 ,  C07H19/10 ,  C08K3/08 ,  C08K2003/0812 ,  C08K2003/0856 ,  C08K2003/0893

Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

公开(公告)号：US10717758B2

公开(公告)日：2020-07-21

申请号：US15981813

申请日：2018-05-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Benjamin Alexander Mayes ,  Adel M. Moussa ,  Alistair James Stewart ,  David Dukhan

IPC: C07H19/20 ,  A61K31/403 ,  C07H19/10 ,  A61K31/7072 ,  A61K45/06 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/4709 ,  A61K31/497 ,  A61K38/21 ,  A61K38/55 ,  C07H19/16 ,  A61K31/7056

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

公开(公告)号：US20190321380A1

公开(公告)日：2019-10-24

申请号：US16471304

申请日：2017-12-19

Applicant: Merck Sharp & Dohme Corp. ,  Idenix Pharmaceuticals LLC

Inventor： Manuel de Lera Ruiz ,  Timothy J. Hartingh ,  Izzat Raheem ,  John Schreier ,  Jean-Laurent Paparin

IPC: A61K31/675 ,  A61P31/18 ,  A61K31/536 ,  A61K31/496 ,  C07D473/34

Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

公开(公告)号：US10363265B2

公开(公告)日：2019-07-30

申请号：US13730669

申请日：2012-12-28

Applicant: Idenix Pharmaceuticals LLC ,  Universita Degli Studi Di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/7072 ,  A61K31/7068 ,  A61K31/708 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/21 ,  G03C1/005

Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.